The Texans re-signed Hansen to a one-year contract Monday, Aaron Wilson of KPRC 2 Houston reports. Hansen appeared in 16 regular-season games for the Texans last season, making two starts. He finished ...

Christopher Bell rallied for an overtime win Sunday at Atlanta Motor Speedway, capturing the Ambetter Health 400 for his 10th career NASCAR Cup Series victory. The Joe Gibbs Racing driver had ...

Between the Class 4A and 3A girls state tournaments, 30 high school basketball games will be played in the Tacoma Dome this weekend. The News Tribune will be at all of them, providing game recaps, ...

Firefighters got applauded, Mick Jagger presented the best original song Oscar and John Lithgow was tasked with looking ...

St. Augustine's Adrian Arbelo (138), Luke Ward (165) and Ron Kraus (190), Mainland Regional’s Chase Hoag (175), Lower’s Bryce ...

NewsNation Washington Correspondent Kellie Meyer joins Bob Sirott to share highlights of President Donald Trump’s conversation with U.K. Prime Minister Starmer and the question she got to ask the ...

A: Carl L. Hansen, CEO, explained that AbCellera is building its translational science and clinical development teams to support its programs. The company is hiring and recruiting based on the ...

Chris Pratt, stunning star from Guardians of ... Full List The King’s Music Room playlists highlights special stories behind Charles’ favourite songs ...

its ability to protect its intellectual property and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's latest ...

In this Healio Video Perspective from SECO 2025, Kristen Brotherson, general manager of U.S. vision care at Alcon, outlined the company’s latest eye care innovations being premiered at the meeting.

Avidity reported its 2025 outlook, including upcoming clinical and regulatory highlights, and recent organization appointments to execute on the full range of strategic initiatives and growth ...

WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation ...